EVI5 is an oncogene that regulates the proliferation and metastasis of NSCLC cells.
EVI5
Emi1
NSCLC
TGF-β receptor I
TGF-β receptor II
miR-486-5p
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
11 May 2020
11 May 2020
Historique:
received:
19
02
2020
accepted:
22
04
2020
entrez:
13
5
2020
pubmed:
13
5
2020
medline:
3
2
2021
Statut:
epublish
Résumé
The Ecotropic viral integration site 5 (EVI5), an important protein in regulating cell cycle, cytokinesis and cellular membrane traffic, functions as a stabilizing factor maintaining anaphase-promoting complex/cyclosome (APC/C) inhibitor Emi1 in S/G2 phase. However, the mechanism by which EVI5 promotes malignant transformation of non-small cell lung cancer (NSCLC) remains unknown. In the present study, we addressed the role of EVI5 in NSCLC by regulating tumor growth, migration and invasion. The expression levels of EVI5 and miR-486-5p in NSCLC tissues and cells were measured by real-time PCR. Meanwhile, EVI5 and its associated protein expression were analyzed by western blot and co-immunoprecipitation assay. Flow cytometry was performed to determine cell proliferation and apoptosis. CCK-8 and clonogenic assays were used to analyze cell viability. Wound healing, transwell migration and matrigel invasion assays were utilized to assess the motility of tumor cells. To investigate the role of EVI5 in vivo, lung carcinoma xenograft mouse model was applied.. EVI5 was upregulated in NSCLC tissues and cell lines when compared with that in normal tissues and cell line. Knockdown of EVI5 in vitro inhibited tumor cell proliferation, migration and invasion in NSCLC cells. Further, inoculation of EVI5-deficient tumor cells into nude mice suppressed tumor proliferation and metastasis compared to control mice inoculated with unmanipulated tumor cells. These data indicated that EVI5 promote the proliferation of NSCLC cells which was consistent with our previous results. Additionally, we showed that EVI5 was directly regulated by miR-486-5p, and miR-486-5p-EVI5 axis affected the NSCLC migration and invasion through TGF-β/Smad signaling pathway by interacting with TGF-β receptor II and TGF-β receptor I. Based on these results, we demonstrated a new post-transcriptional mechanism of EVI5 regulation via miR-486-5p and the protumoral function of EVI5 in NSCLC by interacting with Emi1 and/or TGF-β receptors, which provides a new insight into the targeted therapy of NSCLC.
Sections du résumé
BACKGROUND
BACKGROUND
The Ecotropic viral integration site 5 (EVI5), an important protein in regulating cell cycle, cytokinesis and cellular membrane traffic, functions as a stabilizing factor maintaining anaphase-promoting complex/cyclosome (APC/C) inhibitor Emi1 in S/G2 phase. However, the mechanism by which EVI5 promotes malignant transformation of non-small cell lung cancer (NSCLC) remains unknown. In the present study, we addressed the role of EVI5 in NSCLC by regulating tumor growth, migration and invasion.
METHODS
METHODS
The expression levels of EVI5 and miR-486-5p in NSCLC tissues and cells were measured by real-time PCR. Meanwhile, EVI5 and its associated protein expression were analyzed by western blot and co-immunoprecipitation assay. Flow cytometry was performed to determine cell proliferation and apoptosis. CCK-8 and clonogenic assays were used to analyze cell viability. Wound healing, transwell migration and matrigel invasion assays were utilized to assess the motility of tumor cells. To investigate the role of EVI5 in vivo, lung carcinoma xenograft mouse model was applied..
RESULTS
RESULTS
EVI5 was upregulated in NSCLC tissues and cell lines when compared with that in normal tissues and cell line. Knockdown of EVI5 in vitro inhibited tumor cell proliferation, migration and invasion in NSCLC cells. Further, inoculation of EVI5-deficient tumor cells into nude mice suppressed tumor proliferation and metastasis compared to control mice inoculated with unmanipulated tumor cells. These data indicated that EVI5 promote the proliferation of NSCLC cells which was consistent with our previous results. Additionally, we showed that EVI5 was directly regulated by miR-486-5p, and miR-486-5p-EVI5 axis affected the NSCLC migration and invasion through TGF-β/Smad signaling pathway by interacting with TGF-β receptor II and TGF-β receptor I.
CONCLUSIONS
CONCLUSIONS
Based on these results, we demonstrated a new post-transcriptional mechanism of EVI5 regulation via miR-486-5p and the protumoral function of EVI5 in NSCLC by interacting with Emi1 and/or TGF-β receptors, which provides a new insight into the targeted therapy of NSCLC.
Identifiants
pubmed: 32393392
doi: 10.1186/s13046-020-01585-z
pii: 10.1186/s13046-020-01585-z
pmc: PMC7212589
doi:
Substances chimiques
Cell Cycle Proteins
0
EVI5 protein, human
0
GTPase-Activating Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
84Subventions
Organisme : National Natural Science Foundation of China
ID : 81702870
Organisme : Science and Technology Plan Project of Suzhou
ID : SYS201749
Organisme : Jiangsu Provincial Medical Youth Talent
ID : QNRC2016746
Organisme : Societal and Developmental Project of Suzhou
ID : SS201862
Organisme : Suzhou Key Laboratory for Respiratory Medicine
ID : SZS201617
Organisme : Clinical Medical Center of Suzhou
ID : Szzx201502
Organisme : Jiangsu Provincial Key Medical Discipline
ID : ZDXKB2016007
Références
Cancer Biol Med. 2019 Feb;16(1):66-83
pubmed: 31119047
Biosci Rep. 2011 Jun;31(3):159-68
pubmed: 21250943
Cancer Lett. 2017 Dec 1;410:191-200
pubmed: 28965852
Oncol Rep. 2017 Oct;38(4):2251-2258
pubmed: 28765910
PLoS One. 2019 Sep 4;14(9):e0222083
pubmed: 31483844
Oncogene. 2007 Apr 26;26(19):2804-8
pubmed: 17099728
Trends Cell Biol. 2014 Jul;24(7):407-15
pubmed: 24675420
Cell. 2006 Jan 27;124(2):367-80
pubmed: 16439210
Blood. 2010 Feb 25;115(8):1610-20
pubmed: 20008790
Mol Cell Biol. 2007 Nov;27(22):7955-65
pubmed: 17875940
Blood Cells Mol Dis. 2014 Jan;52(1):68-75
pubmed: 23910958
Cell Signal. 2019 Dec;64:109412
pubmed: 31491459
Int J Mol Sci. 2019 Jun 05;20(11):
pubmed: 31195692
Mol Ther Nucleic Acids. 2019 Jun 7;16:675-685
pubmed: 31121479
Int J Mol Med. 2020 Jun;45(6):1697-1710
pubmed: 32236616
Oncogene. 2014 Feb 27;33(9):1181-9
pubmed: 23474761
Med Sci Monit. 2019 Sep 10;25:6788-6796
pubmed: 31501407
Ann Surg Oncol. 2010 Jul;17(7):1870-7
pubmed: 20221901
Int J Mol Sci. 2019 Oct 31;20(21):
pubmed: 31683709
Curr Top Microbiol Immunol. 2013;367:253-76
pubmed: 23263201
PLoS One. 2019 May 23;14(5):e0217131
pubmed: 31120964
J Cell Biochem. 2019 Aug;120(8):13912-13923
pubmed: 30963622
J Cancer. 2019 Aug 19;10(19):4695-4706
pubmed: 31528235
Oncogene. 2016 Oct 13;35(41):5446-5455
pubmed: 27065322
J Oncol. 2019 Sep 19;2019:7407190
pubmed: 31641356
Oncotarget. 2015 Feb 10;6(4):2421-33
pubmed: 25537516
Nat Rev Mol Cell Biol. 2006 May;7(5):311-22
pubmed: 16633335
J Clin Med. 2019 Jul 03;8(7):
pubmed: 31277295
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Respir Res. 2019 Jul 22;20(1):164
pubmed: 31331328
BMC Res Notes. 2014 Aug 18;7:547
pubmed: 25135188
Mol Cancer. 2017 Feb 3;16(1):34
pubmed: 28158983
Hepatology. 2015 Jan;61(1):361-74
pubmed: 24917558
Cancer Biol Ther. 2014 Oct;15(10):1367-77
pubmed: 25025901
FEBS Lett. 2013 Jun 19;587(12):1703-10
pubmed: 23669355
Biochem Biophys Res Commun. 2019 Nov 12;519(3):489-496
pubmed: 31526565
J Cell Biochem. 2020 Feb;121(2):1953-1962
pubmed: 31633236
Int J Mol Med. 2019 Nov;44(5):1667-1676
pubmed: 31485623
J Cell Biol. 2012 Jul 9;198(1):57-67
pubmed: 22778279
Genes Cells. 2006 Sep;11(9):1023-37
pubmed: 16923123